Effects of T-614, a new antirheumatic drugs, on mononuclear cell function.
نویسندگان
چکیده
منابع مشابه
Kinase inhibitors: a new class of antirheumatic drugs
The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not respond or lose their response over time. The autoimmune process in rheumatoid arthritis depends on ac...
متن کاملAdministration of antirheumatic drugs.
A study of 200 rheumatic patients attending an outpatient clinic and 72 general practitioners (GPs) was undertaken in relation to the administration of antirheumatic drugs. (1) Both patients and GPs agreed that effectiveness, absence of toxicity, and once daily administration were the important features of administration. (2) Significant differences between GPs and patients were noted in that p...
متن کاملeffects of first language on second language writing-a preliminary contrastive rhetoric study of farsi and english
to explore the idea the investingation proposed, aimed at finding whether the performances of the population of iranians students studying english in an efl context are consistent in l1 and l2 writing taks and whether there is a cross-linguistic transfer in this respect. in this regard the subjects were instructed to write four compositions-two in english and two in farsi-which consisted of an ...
15 صفحه اولDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ensho
سال: 1995
ISSN: 0389-4290,1884-4006
DOI: 10.2492/jsir1981.15.55